A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
Top Cited Papers
Open Access
- 1 October 2007
- journal article
- clinical trial
- Published by Elsevier in Cancer Cell
- Vol. 12 (4) , 395-402
- https://doi.org/10.1016/j.ccr.2007.08.030
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapyBritish Journal of Cancer, 2006
- An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitorsNature Chemical Biology, 2006
- PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancerBritish Journal of Cancer, 2006
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005
- A large-scale RNAi screen in human cells identifies new components of the p53 pathwayNature, 2004
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissuesBritish Journal of Cancer, 1996
- Overexpression of p53 and prognosis in breast cancerCancer, 1993